Literature DB >> 27175617

Downregulation of miR-195 promotes prostate cancer progression by targeting HMGA1.

Xiaowen Zhang1, Tao Tao1, Chunhui Liu1, Han Guan1, Yeqing Huang1, Bin Xu1, Ming Chen1.   

Abstract

Aberrant deregulation of microRNA-195 (miR‑195) is associated with tumorigenesis and the development of cancer. However, its expression and function in prostate cancer (PCa) remain to be elucidated. In the present study, we found that miR-195 expression levels were decreased in human PCa samples and were correlated with patient prognosis. miR-195 overexpression inhibited cell proliferation, cell cycle progression and tumorigenesis via directly targeting HMGA1. Downregulation of HMGA1 expression had an effect similar to miR-195 in the PCa cells. In clinical specimens, HMGA1 was overexpressed in castration-resistant prostate cancer when compared with its levels in benign prostate hyperplasia and androgen-dependent prostate cancer, and its expression levels were inversely correlated with overall survival and biochemical relapse-free survival. In summary, our study suggests that miR-195 functions as a tumor-suppressor gene by downregulating HMGA1 and can be used as a potential target in the treatment of PCa.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27175617     DOI: 10.3892/or.2016.4797

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  18 in total

1.  Identification of Potential miRNAs Biomarkers for High-Grade Prostate Cancer by Integrated Bioinformatics Analysis.

Authors:  Laura Foj; Xavier Filella
Journal:  Pathol Oncol Res       Date:  2018-10-26       Impact factor: 3.201

2.  MicroRNA-296-5p inhibits cell proliferation by targeting HMGA1 in colorectal cancer.

Authors:  Guohui Yan; Shuidi Yan; Jiajia Wang; Shen Lei; Weimin Tian; Xin Yue; Yang Zhang
Journal:  Exp Ther Med       Date:  2021-05-24       Impact factor: 2.447

3.  Overexpression of SOX4 induces up-regulation of miR-126 and miR-195 in LNCaP prostate cancer cell line.

Authors:  Nam Nhut Phan; Carlos S Moreno; Yu-Heng Lai
Journal:  Cytotechnology       Date:  2020-05-17       Impact factor: 2.058

4.  Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer.

Authors:  Muralidharan Jayaraman; Rangasudhagar Radhakrishnan; Cara A Mathews; Mingda Yan; Sanam Husain; Katherine M Moxley; Yong Sang Song; Danny N Dhanasekaran
Journal:  Genes Cancer       Date:  2017-05

5.  miR-195 Regulates Proliferation and Apoptosis through Inhibiting the mTOR/p70s6k Signaling Pathway by Targeting HMGA2 in Esophageal Carcinoma Cells.

Authors:  Yong Li; Dapeng Wu; Pei Wang; Xiaohui Li; Gongning Shi
Journal:  Dis Markers       Date:  2017-04-09       Impact factor: 3.434

6.  Decrease of miR-195 Promotes Chondrocytes Proliferation and Maintenance of Chondrogenic Phenotype via Targeting FGF-18 Pathway.

Authors:  Yong Wang; Tao Yang; Yadong Liu; Wei Zhao; Zhen Zhang; Ming Lu; Weiguo Zhang
Journal:  Int J Mol Sci       Date:  2017-05-04       Impact factor: 5.923

Review 7.  MicroRNAs and epithelial-mesenchymal transition in prostate cancer.

Authors:  Kirandeep Sekhon; Nathan Bucay; Shahana Majid; Rajvir Dahiya; Sharanjot Saini
Journal:  Oncotarget       Date:  2016-10-11

8.  Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.

Authors:  Ion Cristóbal; Blanca Torrejón; Juan Madoz-Gúrpide; Federico Rojo; Jesús García-Foncillas
Journal:  Br J Cancer       Date:  2016-12-20       Impact factor: 7.640

Review 9.  Ailanthone: A novel potential drug for treating human cancer.

Authors:  Haixiang Ding; Xiuchong Yu; Chen Hang; Kaijun Gao; Xifeng Lao; Yangtao Jia; Zhilong Yan
Journal:  Oncol Lett       Date:  2020-06-09       Impact factor: 2.967

10.  Expression of miR-451a in Prostate Cancer and Its Effect on Prognosis.

Authors:  Bo Fan; Xiaohua Jin; Qi Ding; Cheng Cao; Yi Shi; Hailiang Zhu; Wenjun Zhou
Journal:  Iran J Public Health       Date:  2021-04       Impact factor: 1.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.